阿立哌唑月桂醇纳米晶®分散技术(Aristada Initio®)。

Q4 Medicine

Clinical Schizophrenia and Related Psychoses Pub Date : 2018-01-01 DOI:10.3371/CSRP.EHDA071918

Megan J Ehret, Erica Davis, Sarah E Luttrell, Caroline Clark

{"title":"阿立哌唑月桂醇纳米晶®分散技术(Aristada Initio®)。","authors":"Megan J Ehret, Erica Davis, Sarah E Luttrell, Caroline Clark","doi":"10.3371/CSRP.EHDA071918","DOIUrl":null,"url":null,"abstract":"Nonadherence to antipsychotic medications for the treatment of schizophrenia is a widely recognized concern, leading to poorer clinical outcomes and higher treatment costs. Long-acting injectable (LAI) antipsychotics offer an extended dosing interval option for patients, although the current options may require an oral overlap at initiation. Aripiprazole lauroxil is an LAI that offers multiple dosing options but requires oral treatment overlap during initiation for the first 21 consecutive days. As an alternative to oral overlap, a novel nano-crystalline milled dispersion delivery system of aripiprazole lauroxil was recently approved as a one-day regimen to be added to aripiprazole lauroxil treatment.","PeriodicalId":40019,"journal":{"name":"Clinical Schizophrenia and Related Psychoses","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"14","resultStr":"{\"title\":\"Aripiprazole Lauroxil NanoCrystal® Dispersion Technology (Aristada Initio®).\",\"authors\":\"Megan J Ehret, Erica Davis, Sarah E Luttrell, Caroline Clark\",\"doi\":\"10.3371/CSRP.EHDA071918\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Nonadherence to antipsychotic medications for the treatment of schizophrenia is a widely recognized concern, leading to poorer clinical outcomes and higher treatment costs. Long-acting injectable (LAI) antipsychotics offer an extended dosing interval option for patients, although the current options may require an oral overlap at initiation. Aripiprazole lauroxil is an LAI that offers multiple dosing options but requires oral treatment overlap during initiation for the first 21 consecutive days. As an alternative to oral overlap, a novel nano-crystalline milled dispersion delivery system of aripiprazole lauroxil was recently approved as a one-day regimen to be added to aripiprazole lauroxil treatment.\",\"PeriodicalId\":40019,\"journal\":{\"name\":\"Clinical Schizophrenia and Related Psychoses\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"14\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Schizophrenia and Related Psychoses\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3371/CSRP.EHDA071918\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Schizophrenia and Related Psychoses","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3371/CSRP.EHDA071918","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 14

摘要

治疗精神分裂症的抗精神病药物不依从性是一个广泛关注的问题，导致较差的临床结果和较高的治疗费用。长效注射(LAI)抗精神病药物为患者提供了延长给药间隔的选择，尽管目前的选择可能需要在开始时口服重叠。阿立哌唑lauroxil是一种LAI，提供多种给药选择，但在开始期间需要连续21天的口服治疗重叠。作为口服重叠的替代方案，一种新型纳米晶体研磨分散递送系统最近被批准作为阿立哌唑月桂醇治疗的一天方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Aripiprazole Lauroxil NanoCrystal^® Dispersion Technology (Aristada Initio^®).

Nonadherence to antipsychotic medications for the treatment of schizophrenia is a widely recognized concern, leading to poorer clinical outcomes and higher treatment costs. Long-acting injectable (LAI) antipsychotics offer an extended dosing interval option for patients, although the current options may require an oral overlap at initiation. Aripiprazole lauroxil is an LAI that offers multiple dosing options but requires oral treatment overlap during initiation for the first 21 consecutive days. As an alternative to oral overlap, a novel nano-crystalline milled dispersion delivery system of aripiprazole lauroxil was recently approved as a one-day regimen to be added to aripiprazole lauroxil treatment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Schizophrenia and Related Psychoses Medicine-Psychiatry and Mental Health

自引率

0.00%

发文量

期刊介绍： The vision of the exciting new peer-reviewed quarterly publication Clinical Schizophrenia & Related Psychoses (CS) is to provide psychiatrists and other healthcare professionals with the latest research and advances in the diagnosis and treatment of schizophrenia and related psychoses. CS is a practice-oriented publication focused exclusively on the newest research findings, guidelines, treatment protocols, and clinical trials relevant to patient care.